321 related articles for article (PubMed ID: 30382947)
1. Targeting the divergent TGFβ superfamily cytokine MIC-1/GDF15 for therapy of anorexia/cachexia syndromes.
Tsai VW; Brown DA; Breit SN
Curr Opin Support Palliat Care; 2018 Dec; 12(4):404-409. PubMed ID: 30382947
[TBL] [Abstract][Full Text] [Related]
2. Anorexia-cachexia and obesity treatment may be two sides of the same coin: role of the TGF-b superfamily cytokine MIC-1/GDF15.
Tsai VW; Lin S; Brown DA; Salis A; Breit SN
Int J Obes (Lond); 2016 Feb; 40(2):193-7. PubMed ID: 26620888
[TBL] [Abstract][Full Text] [Related]
3. The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases.
Tsai VWW; Husaini Y; Sainsbury A; Brown DA; Breit SN
Cell Metab; 2018 Sep; 28(3):353-368. PubMed ID: 30184485
[TBL] [Abstract][Full Text] [Related]
4. Targeting Obesity and Cachexia: Identification of the GFRAL Receptor-MIC-1/GDF15 Pathway.
Breit SN; Tsai VW; Brown DA
Trends Mol Med; 2017 Dec; 23(12):1065-1067. PubMed ID: 29129392
[TBL] [Abstract][Full Text] [Related]
5. Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond.
Mullican SE; Rangwala SM
Trends Endocrinol Metab; 2018 Aug; 29(8):560-570. PubMed ID: 29866502
[TBL] [Abstract][Full Text] [Related]
6. The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?
Breit SN; Brown DA; Tsai VW
Annu Rev Physiol; 2021 Feb; 83():127-151. PubMed ID: 33228454
[TBL] [Abstract][Full Text] [Related]
7. The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism.
Breit SN; Johnen H; Cook AD; Tsai VW; Mohammad MG; Kuffner T; Zhang HP; Marquis CP; Jiang L; Lockwood G; Lee-Ng M; Husaini Y; Wu L; Hamilton JA; Brown DA
Growth Factors; 2011 Oct; 29(5):187-95. PubMed ID: 21831009
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia.
Siddiqui JA; Pothuraju R; Khan P; Sharma G; Muniyan S; Seshacharyulu P; Jain M; Nasser MW; Batra SK
Cytokine Growth Factor Rev; 2022 Apr; 64():71-83. PubMed ID: 34836750
[TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice.
Suriben R; Chen M; Higbee J; Oeffinger J; Ventura R; Li B; Mondal K; Gao Z; Ayupova D; Taskar P; Li D; Starck SR; Chen HH; McEntee M; Katewa SD; Phung V; Wang M; Kekatpure A; Lakshminarasimhan D; White A; Olland A; Haldankar R; Solloway MJ; Hsu JY; Wang Y; Tang J; Lindhout DA; Allan BB
Nat Med; 2020 Aug; 26(8):1264-1270. PubMed ID: 32661391
[TBL] [Abstract][Full Text] [Related]
10. Anorexia/cachexia of chronic diseases: a role for the TGF-β family cytokine MIC-1/GDF15.
Tsai VW; Husaini Y; Manandhar R; Lee-Ng KK; Zhang HP; Harriott K; Jiang L; Lin S; Sainsbury A; Brown DA; Breit SN
J Cachexia Sarcopenia Muscle; 2012 Dec; 3(4):239-43. PubMed ID: 22936174
[TBL] [Abstract][Full Text] [Related]
11. GDF15 mediates adiposity resistance through actions on GFRAL neurons in the hindbrain AP/NTS.
Tsai VW; Zhang HP; Manandhar R; Schofield P; Christ D; Lee-Ng KKM; Lebhar H; Marquis CP; Husaini Y; Brown DA; Breit SN
Int J Obes (Lond); 2019 Dec; 43(12):2370-2380. PubMed ID: 31152154
[TBL] [Abstract][Full Text] [Related]
12. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.
Emmerson PJ; Wang F; Du Y; Liu Q; Pickard RT; Gonciarz MD; Coskun T; Hamang MJ; Sindelar DK; Ballman KK; Foltz LA; Muppidi A; Alsina-Fernandez J; Barnard GC; Tang JX; Liu X; Mao X; Siegel R; Sloan JH; Mitchell PJ; Zhang BB; Gimeno RE; Shan B; Wu X
Nat Med; 2017 Oct; 23(10):1215-1219. PubMed ID: 28846098
[TBL] [Abstract][Full Text] [Related]
13. LPS induces rapid increase in GDF15 levels in mice, rats, and humans but is not required for anorexia in mice.
Patel AR; Frikke-Schmidt H; Bezy O; Sabatini PV; Rittig N; Jessen N; Myers MG; Seeley RJ
Am J Physiol Gastrointest Liver Physiol; 2022 Feb; 322(2):G247-G255. PubMed ID: 34935522
[TBL] [Abstract][Full Text] [Related]
14. Anorexia-cachexia syndrome in hepatoma tumour-bearing rats requires the area postrema but not vagal afferents and is paralleled by increased MIC-1/GDF15.
Borner T; Arnold M; Ruud J; Breit SN; Langhans W; Lutz TA; Blomqvist A; Riediger T
J Cachexia Sarcopenia Muscle; 2017 Jun; 8(3):417-427. PubMed ID: 28025863
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of GDF15 Prevents Anorexia and Weight Loss in the Monocrotaline-Induced Cardiac Cachexia Rat Model.
Albuquerque B; Chen X; Hirenallur-Shanthappa D; Zhao Y; Stansfield JC; Zhang BB; Sheikh A; Wu Z
Cells; 2022 Mar; 11(7):. PubMed ID: 35406637
[TBL] [Abstract][Full Text] [Related]
16. GDF15: A Hormone Conveying Somatic Distress to the Brain.
Lockhart SM; Saudek V; O'Rahilly S
Endocr Rev; 2020 Aug; 41(4):. PubMed ID: 32310257
[TBL] [Abstract][Full Text] [Related]
17. GDF15, an update of the physiological and pathological roles it plays: a review.
Assadi A; Zahabi A; Hart RA
Pflugers Arch; 2020 Nov; 472(11):1535-1546. PubMed ID: 32936319
[TBL] [Abstract][Full Text] [Related]
18. GDNF family receptor alpha-like antagonist antibody alleviates chemotherapy-induced cachexia in melanoma-bearing mice.
Lee BY; Jeong J; Jung I; Cho H; Jung D; Shin J; Park JK; Park E; Noh S; Shin S; Kang S; Heo JI; Baek MC; Yea K
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1441-1453. PubMed ID: 37017344
[TBL] [Abstract][Full Text] [Related]
19. Identification of GDF15 peptide fragments inhibiting GFRAL receptor signaling.
Alexopoulou F; Buch-Månson N; Pedersen SL; Vrang N; Fink LN; Strømgaard K
Peptides; 2023 Oct; 168():171063. PubMed ID: 37495041
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study.
Cheung CL; Tan KCB; Au PCM; Li GHY; Cheung BMY
EBioMedicine; 2019 Mar; 41():85-90. PubMed ID: 30772304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
